Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/173783
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Salazar Soler, Ramón | - |
dc.contributor.author | Capdevila, Jaume | - |
dc.contributor.author | Manzano, José Luis | - |
dc.contributor.author | Pericay, Carles | - |
dc.contributor.author | Martínez Villacampa, Mercedes | - |
dc.contributor.author | López, Carlos | - |
dc.contributor.author | Losa, Ferrán | - |
dc.contributor.author | Safont, María José | - |
dc.contributor.author | Gómez Espana, Auxiliadora | - |
dc.contributor.author | Alonso Orduña, Vicente | - |
dc.contributor.author | Escudero, Pilar | - |
dc.contributor.author | Gallego, Javier | - |
dc.contributor.author | García Paredes, Beatriz | - |
dc.contributor.author | Palacios, Amalia | - |
dc.contributor.author | Biondo, Sebastián | - |
dc.contributor.author | Grávalos, Cristina | - |
dc.contributor.author | Aranda, Enrique | - |
dc.contributor.author | Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD) | - |
dc.date.accessioned | 2021-02-10T08:52:18Z | - |
dc.date.available | 2021-02-10T08:52:18Z | - |
dc.date.issued | 2020-12-27 | - |
dc.identifier.uri | http://hdl.handle.net/2445/173783 | - |
dc.description.abstract | Background: Preoperative chemoradiotherapy with capecitabine is considered as a standard of care for locally advanced rectal cancer. The “Tratamiento de Tumores Digestivos” group (TTD) previously reported in a randomized Ph II study that the addition of Bevacizumab to capecitabine-RT conferred no differences in the pre-defined efficacy endpoint (pathological complete response). We present the follow-up results of progression-free survival, distant relapse-free survival, and overall survival data at 3 and 5 years. Methods: Patients (pts) were randomized to receive 5 weeks of radiotherapy (45 Gy/25 fractions) with concurrent Capecitabine 825 mg/m2 twice daily, 5 days per week with (arm A) or without (arm b) bevacizumab (5 mg/kg once every 2 weeks). Results: In our study, the addition of bevacizumab to capecitabine and radiotherapy in the neoadjuvant setting shows no differences in pathological complete response (15.9% vs 10.9%), distant relapse-free survival (81.0 vs 80.4 and 76.2% vs 78.2% at 3 and 5 years respectively), disease-free survival (75% vs 71.7 and 68.1% vs 69.57% at 3 and 5 years respectively) nor overall survival at 5-years of follow-up (81.8% vs 86.9%). Conclusions: the addition of bevacizumab to capecitabine plus radiotherapy does not confer statistically significant advantages neither in distant relapse-free survival nor in disease-free survival nor in Overall Survival in the short or long term. | - |
dc.format.extent | 11 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | BioMed Central | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1186/s12885-020-07661-z | - |
dc.relation.ispartof | BMC Cancer, 2020, vol. 20 | - |
dc.relation.uri | https://doi.org/10.1186/s12885-020-07661-z | - |
dc.rights | cc by (c) Salazar Soler et al., 2020 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | - |
dc.source | Articles publicats en revistes (Ciències Clíniques) | - |
dc.subject.classification | Càncer colorectal | - |
dc.subject.classification | Quimioteràpia | - |
dc.subject.classification | Radioteràpia | - |
dc.subject.mesh | Colorectal cancer | - |
dc.subject.other | Chemotherapy | - |
dc.subject.other | Radiotherapy | - |
dc.title | Phase II randomized trial of capecitabine with bevacizumab and external beam radiation therapy as preoperative treatment for patients with resectable locally advanced rectal adenocarcinoma: long term results | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 709274 | - |
dc.date.updated | 2021-02-08T10:14:12Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 33246428 | - |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) Articles publicats en revistes (Ciències Clíniques) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
SalazarR.pdf | 723 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License